FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 320:473-478 February 23, 1989 Number 8 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

We evaluated the postoperative use of sequential methotrexate and fluorouracil followed by leucovorin in 679 patients with primary breast cancer, histologically negative axillary nodes, and estrogen-receptor-negative (less than 10 fmol) tumors. No survival advantage was observed with this therapy as compared with no postoperative therapy during four years of follow-up (87 percent vs. 86 percent; P = 0.8). However, there was a significant prolongation of disease-free survival among women who received this therapy as compared with those who did not (80 percent vs. 71 percent; P = 0.003). An advantage was observed in both the patients less than or equal to 49 years old and those greater than or equal to 50. At four years, treatment failure was reduced by 24 percent in the younger group and by 50 percent in the older group. The rates of both local and regional and distant metastases were decreased. These benefits, achieved without the use of an alkylating agent, were associated with tolerable side effects. Multivariate analysis testing for potential interactions failed to identify subgroups of patients who did not benefit from the therapy. These results, although promising, do not obviate the need for additional trials to evaluate potentially better regimens of therapy, but they do suggest that sequential methotrexate-fluorouracil should be used in the control arm in such studies. Their use is also justified for the treatment of patients who refuse to participate in clinical trials, provided the patients meet the eligibility criteria of the present study. Since women with tumors too small for conventional analysis of estrogen-receptor and progesterone-receptor concentrations were not included in this study, we do not recommend systemic treatment for them outside of a clinical trial.

Source Information

National Surgical Adjuvant Breast and Bowel Project (NSABP) Headquarters, Pittsburgh, PA 15261.

This article has been cited by other articles:

• Fisher, B., Redmond, C. K., Fisher, E. R. (2008). Evolution of Knowledge Related to Breast Cancer Heterogeneity: A 25-Year Retrospective. JCO 26: 2068-2071 [Full Text]  
• Samphao, S., Eremin, J. M., El-Sheemy, M., Eremin, O. (2008). Management of the Axilla in Women With Breast Cancer: Current Clinical Practice and a New Selective Targeted Approach. Ann. Surg. Oncol. 15: 1282-1296 [Abstract] [Full Text]  
• Jeong, J.-H., Fine, J. P. (2007). Parametric regression on cumulative incidence function. Biostatistics 8: 184-196 [Abstract] [Full Text]  
• Taghian, A. G., Jeong, J.-H., Mamounas, E. P., Parda, D. S., Deutsch, M., Costantino, J. P., Wolmark, N. (2006). Low Locoregional Recurrence Rate Among Node-Negative Breast Cancer Patients With Tumors 5 cm or Larger Treated by Mastectomy, With or Without Adjuvant Systemic Therapy and Without Radiotherapy: Results From Five National Surgical Adjuvant Breast and Bowel Project Randomized Clinical Trials. JCO 24: 3927-3932 [Abstract] [Full Text]  
• Hanrahan, E. O., Valero, V., Gonzalez-Angulo, A. M., Hortobagyi, G. N. (2006). Prognosis and Management of Patients With Node-Negative Invasive Breast Carcinoma That Is 1 cm or Smaller in Size (stage 1; T1a,bN0M0): A Review of the Literature. JCO 24: 2113-2122 [Abstract] [Full Text]  
• Albain, K. S. (2004). Adjuvant Chemotherapy for Lymph Node-Negative, Estrogen Receptor-Negative Breast Cancer: A Tale of Three Trials. JNCI J Natl Cancer Inst 96: 1801-1804 [Full Text]  
• Fisher, B., Jeong, J.-H., Anderson, S., Wolmark, N. (2004). Treatment of Axillary Lymph Node-Negative, Estrogen Receptor-Negative Breast Cancer: Updated Findings From National Surgical Adjuvant Breast and Bowel Project Clinical Trials. JNCI J Natl Cancer Inst 96: 1823-1831 [Abstract] [Full Text]  
• Mandelblatt, J. S., Schechter, C. B., Yabroff, K. R., Lawrence, W., Dignam, J., Muennig, P., Chavez, Y., Cullen, J., Fahs, M. (2004). Benefits and Costs of Interventions to Improve Breast Cancer Outcomes in African American Women. JCO 22: 2554-2566 [Abstract] [Full Text]  
• Bull, S. B., Ozcelik, H., Pinnaduwage, D., Blackstein, M. E., Sutherland, D. A.J., Pritchard, K. I., Tzontcheva, A. T., Sidlofsky, S., Hanna, W. M., Qizilbash, A. H., Tweeddale, M. E., Fine, S., McCready, D. R., Andrulis, I. L. (2004). The Combination of p53 Mutation and neu/erbB-2 Amplification Is Associated With Poor Survival in Node-Negative Breast Cancer. JCO 22: 86-96 [Abstract] [Full Text]  
• International Breast Cancer Study Group, (2003). Adjuvant Chemotherapy Followed by Goserelin Versus Either Modality Alone for Premenopausal Lymph Node-Negative Breast Cancer: A Randomized Trial. JNCI J Natl Cancer Inst 95: 1833-1846 [Abstract] [Full Text]  
• Mamounas, E. P. (2003). NSABP Breast Cancer Clinical Trials: Recent Results and Future Directions. Clin Med Res 1: 309-326 [Abstract] [Full Text]  
• Fant, J. S., Grant, M. D., Knox, S. M., Livingston, S. A., Ridl, K., Jones, R. C., Kuhn, J. A. (2003). Preliminary Outcome Analysis in Patients With Breast Cancer and a Positive Sentinel Lymph Node Who Declined Axillary Dissection. Ann. Surg. Oncol. 10: 126-130 [Abstract] [Full Text]  
• Mariotto, A., Feuer, E. J., Harlan, L. C., Wun, L.-M., Johnson, K. A., Abrams, J. (2002). Trends in Use of Adjuvant Multi-Agent Chemotherapy and Tamoxifen for Breast Cancer in the United States: 1975-1999. JNCI J Natl Cancer Inst 94: 1626-1634 [Abstract] [Full Text]  
• Mirza, N. Q., Vlastos, G., Meric, F., Buchholz, T. A., Esnaola, N., Singletary, S. E., Kuerer, H. M., Newman, L. A., Ames, F. C., Ross, M. I., Feig, B. W., Pollock, R. E., McNeese, M., Strom, E., Hunt, K. K. (2002). Predictors of Locoregional Recurrence Among Patients With Early-Stage Breast Cancer Treated With Breast-Conserving Therapy. Ann. Surg. Oncol. 9: 256-265 [Abstract] [Full Text]  
• Fisher, B., Jeong, J.-H., Dignam, J., Anderson, S., Mamounas, E., Wickerham, D. L., Wolmark, N. (2001). Findings From Recent National Surgical Adjuvant Breast and Bowel Project Adjuvant Studies in Stage I Breast Cancer. J Natl Cancer Inst Monogr 2001: 62-66 [Abstract] [Full Text]  
• Hortobagyi, G. N (2001). Progress in Systemic Chemotherapy of Primary Breast Cancer: an Overview. J Natl Cancer Inst Monogr 2001: 72-79 [Abstract] [Full Text]  
• Paradiso, A., Schittulli, F., Cellamare, G., Mangia, A., Marzullo, F., Lorusso, V., De Lena, M. (2001). Randomized Clinical Trial of Adjuvant Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy for Patients With Fast-Proliferating, Node-Negative Breast Cancer. JCO 19: 3929-3937 [Abstract] [Full Text]  
• Fisher, B., Anderson, S., Tan-Chiu, E., Wolmark, N., Wickerham, D. L., Fisher, E. R., Dimitrov, N. V., Atkins, J. N., Abramson, N., Merajver, S., Romond, E. H., Kardinal, C. G., Shibata, H. R., Margolese, R. G., Farrar, W. B. (2001). Tamoxifen and Chemotherapy for Axillary Node-Negative, Estrogen Receptor-Negative Breast Cancer: Findings From National Surgical Adjuvant Breast and Bowel Project B-23. JCO 19: 931-942 [Abstract] [Full Text]  
• Gerber, B., Krause, A., Muller, H., Richter, D., Reimer, T., Makovitzky, J., Herrnring, C., Jeschke, U., Kundt, G., Friese, K. (2001). Simultaneous Immunohistochemical Detection of Tumor Cells in Lymph Nodes and Bone Marrow Aspirates in Breast Cancer and Its Correlation With Other Prognostic Factors. JCO 19: 960-971 [Abstract] [Full Text]  
• Fisher, B., Dignam, J., Tan-Chiu, E., Anderson, S., Fisher, E. R., Wittliff, J. L., Wolmark, N. (2001). Prognosis and Treatment of Patients With Breast Tumors of One Centimeter or Less and Negative Axillary Lymph Nodes. JNCI J Natl Cancer Inst 93: 112-120 [Abstract] [Full Text]  
• Reed, D. N. Jr, Johnson, J., Richard, P., McCormick, S., Shannon, N., Mikhail, R. A., Osuch, J., Cerrito, P. B., McMasters, K. M. (2000). DNA Flow Cytometry Does Not Predict 5- or 10-Year Recurrence Rates for T1-2 Node-Negative Breast Cancer. Arch Surg 135: 1422-1426 [Abstract] [Full Text]  
• Amadori, D., Nanni, O., Marangolo, M., Pacini, P., Ravaioli, A., Rossi, A., Gambi, A., Catalano, G., Perroni, D., Scarpi, E., Giunchi, D. C., Tienghi, A., Becciolini, A., Volpi, A. (2000). Disease-Free Survival Advantage of Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Patients With Node-Negative, Rapidly Proliferating Breast Cancer: A Randomized Multicenter Study. JCO 18: 3125-3134 [Abstract] [Full Text]  
• Wolff, A. C., Davidson, N. E. (2000). Primary Systemic Therapy in Operable Breast Cancer. JCO 18: 1558-1569 [Abstract] [Full Text]  
• Gail, M. H., Costantino, J. P., Bryant, J., Croyle, R., Freedman, L., Helzlsouer, K., Vogel, V. (1999). Weighing the Risks and Benefits of Tamoxifen Treatment for Preventing Breast Cancer. JNCI J Natl Cancer Inst 91: 1829-1846 [Abstract] [Full Text]  
• Thames, H. D., Buchholz, T. A., Smith, C. D. (1999). Frequency of First Metastatic Events in Breast Cancer: Implications for Sequencing of Systemic and Local-Regional Treatment. JCO 17: 2649-2649 [Abstract] [Full Text]  
• Hebert-Croteau, N., Brisson, J., Latreille, J., Gariepy, G., Blanchette, C., Deschenes, L. (1999). Time Trends in Systemic Adjuvant Treatment for Node-Negative Breast Cancer. JCO 17: 1458-1458 [Abstract] [Full Text]  
• Ollila, D. W., Brennan, M. B., Giuliano, A. E. (1998). Therapeutic Effect of Sentinel Lymphadenectomy in T1 Breast Cancer. Arch Surg 133: 647-651 [Abstract] [Full Text]  
• Angell, M., Kassirer, J. P. (1994). Setting the Record Straight in the Breast-Cancer Trials. NEJM 330: 1448-1450 [Full Text]  
• Fisher, B., Redmond, C. K., Poisson, R., Broder, S., Bivens, L. W., Macfarlane, D. K., Bernier, G. M., Huet, P.-M., Richer, G. (1994). Fraud in Breast-Cancer Trials. NEJM 330: 1458-1462 [Full Text]  
• Lo, B. (1992). Ethical Dilemmas in HIV Infection: What Have We Learned?. J Law Med Ethics 20: 92-103  
• (1989). ADJUVANT SYSTEMIC THERAPY FOR NODE-NEGATIVE BREAST CANCER. JWatch General 1989: 1-1 [Full Text]